期刊
FRONTIERS IN ONCOLOGY
卷 9, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2019.00506
关键词
isocitrate dehydrogenase; glioma; IDH inhibitor; IDH vaccine; 2-hydroxyglutaric acid
类别
资金
- Open Project Funding of Key Laboratory of Basic Pharmacology and Joint International Research Laboratory of Ethnomedicine of Ministry of Education [JCYL-K-012]
- Guizhou Province's Thousand-Level Innovative Talents [2015-25]
- 15851 Talent Elite Project, Guizhou Provincial Department of Science and Technology [2017-5782]
- Science and Technology Joint Funds of Zunyi Science and Technology Bureau [2018-183, 2018-23]
- Zunyi Medical University [F-900]
Isocitrate dehydrogenase (IDH) is a key rate-limiting enzyme in the Krebs cycle that plays an important role in energy metabolism. In recent years, it has been found that IDH mutations are closely related to the occurrence and development of glioma, and it is a notable potential therapeutic target. First, IDH mutations can produce high levels of 2-hydroxyglutaric acid (2-HG), thereby inhibiting glioma stem cell differentiation. At the same time, IDH mutations can upregulate vascular endothelial growth factor (VEGF) to promote the formation of the tumor microenvironment. In addition, IDH mutations can also induce high levels of hypoxia-inducible factor-1 alpha (HIF-1 alpha) to promote glioma invasion. Ultimately, these changes will lead to the development of glioma. Currently, a large number of IDH inhibitors and vaccines have entered clinical trials, representing progress in the treatment of glioma patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据